Cholangiocarcinoma Education
Cholangiocarcinoma is one of the fastest-growing oncology segments, with FGFR inhibitors, IDH1-targeted therapy, and immunotherapy combinations creating a new precision medicine paradigm. Knowledge Med sessions help physicians navigate biomarker-driven treatment decisions through interactive case simulations.
Non-promotional, independently reviewed sessions led by faculty from Johns Hopkins, Columbia, Mount Sinai, and other leading academic medical centers.
What Providers Navigate
Physicians managing cholangiocarcinoma & biliary tract cancer face evolving treatment decisions that interactive, independently reviewed education can help address.
- Ensuring comprehensive molecular profiling (FGFR2 fusions, IDH1, HER2, MSI-H) at diagnosis
- Selecting between gemcitabine-cisplatin-durvalumab and other first-line combinations
- Integrating FGFR inhibitors (pemigatinib, futibatinib) and ivosidenib for actionable targets
- Managing intrahepatic vs extrahepatic vs gallbladder cancer treatment nuances
What Sessions Cover
Knowledge Med CCA sessions use interactive case simulations to address these topics and more.
- First-line immunotherapy-chemotherapy in advanced biliary tract cancer
- Biomarker-driven targeted therapy: FGFR2, IDH1, and beyond
- Molecular profiling strategies and next-generation sequencing in CCA
- Emerging targets: HER2, BRAF, and novel combination approaches
Interactive CCA Sessions
Case Simulations
Work through realistic cholangiocarcinoma & biliary tract cancer patient cases with expert faculty, making treatment decisions at each stage.
Live Polling
See how your clinical decisions compare to peers in real time — revealing practice patterns and knowledge gaps.
Personalized Report
Receive a session summary with your individual responses, peer benchmarks, and key CCA clinical takeaways.
More Solid Tumor Sessions
Knowledge Med offers interactive sessions across many indications — these are just some of the areas we cover.
Metastatic Colorectal Cancer
mCRC — Biomarker-driven first-line therapy selection in mCRC
HER2-Positive Breast Cancer
HER2+ — First-line treatment selection in HER2+ metastatic breast cancer
Metastatic Breast Cancer
mBC — First-line endocrine-based therapy selection in HR+/HER2- mBC
Triple-Negative Breast Cancer
TNBC — Immunotherapy in first-line metastatic TNBC: patient selection and regimens
Join a CCA Session
Third-party, non-promotional cholangiocarcinoma & biliary tract cancer education led by faculty from leading academic medical centers. Case simulations. Live polling. Personalized insights.
Join a Session